CO7071139A2 - Tratamiento contra el cáncer cerebral - Google Patents

Tratamiento contra el cáncer cerebral

Info

Publication number
CO7071139A2
CO7071139A2 CO14208829A CO14208829A CO7071139A2 CO 7071139 A2 CO7071139 A2 CO 7071139A2 CO 14208829 A CO14208829 A CO 14208829A CO 14208829 A CO14208829 A CO 14208829A CO 7071139 A2 CO7071139 A2 CO 7071139A2
Authority
CO
Colombia
Prior art keywords
brain cancer
cancer treatment
compounds
treatment against
against brain
Prior art date
Application number
CO14208829A
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7071139(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO7071139A2 publication Critical patent/CO7071139A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan en la presente compuestos para el tratamiento contra el cáncer cerebral. Además, se proporcionan en la presente composiciones farmacéuticas que integran esos compuestos para el tratamiento contra el cáncer cerebral.
CO14208829A 2012-03-23 2014-09-19 Tratamiento contra el cáncer cerebral CO7071139A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23

Publications (1)

Publication Number Publication Date
CO7071139A2 true CO7071139A2 (es) 2014-09-30

Family

ID=48048296

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14208829A CO7071139A2 (es) 2012-03-23 2014-09-19 Tratamiento contra el cáncer cerebral

Country Status (30)

Country Link
US (3) US20150110780A1 (es)
EP (4) EP3400943B1 (es)
JP (6) JP2015514075A (es)
KR (3) KR102317166B1 (es)
CN (2) CN104203279B (es)
AU (4) AU2013234921A1 (es)
CA (1) CA2867723C (es)
CL (1) CL2014002497A1 (es)
CO (1) CO7071139A2 (es)
CY (2) CY1120204T1 (es)
DK (2) DK2827900T3 (es)
ES (2) ES2855142T3 (es)
HK (1) HK1206276A1 (es)
HR (1) HRP20180659T1 (es)
HU (2) HUE053156T2 (es)
IL (3) IL234627B (es)
LT (1) LT2827900T (es)
MX (1) MX354024B (es)
MY (2) MY174883A (es)
NZ (4) NZ756264A (es)
PH (1) PH12014502032A1 (es)
PL (2) PL3400943T3 (es)
PT (2) PT3400943T (es)
RS (1) RS57140B1 (es)
RU (2) RU2672575C2 (es)
SG (1) SG11201405954YA (es)
SI (2) SI2827900T1 (es)
TR (1) TR201808450T4 (es)
UA (1) UA122044C2 (es)
WO (1) WO2013142875A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
CA3055957A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
WO2019197973A1 (en) * 2018-04-09 2019-10-17 Moshe Giladi Treating tumors with ttfields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
PL4084778T3 (pl) 2019-12-30 2024-03-04 Deciphera Pharmaceuticals, Llc Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
CN103772373B (zh) 2003-08-14 2017-06-09 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
BR122018075851B1 (pt) 2005-11-15 2022-01-11 Array Biopharma Inc Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+

Also Published As

Publication number Publication date
ES2673165T3 (es) 2018-06-20
DK2827900T3 (en) 2018-05-07
IL261659A (en) 2018-10-31
KR102490961B1 (ko) 2023-01-19
MY174883A (en) 2020-05-20
HK1206276A1 (en) 2016-01-08
PT2827900T (pt) 2018-06-14
PL2827900T3 (pl) 2018-08-31
NZ630843A (en) 2017-01-27
NZ756264A (en) 2022-09-30
JP2017141302A (ja) 2017-08-17
DK3400943T3 (da) 2021-02-08
WO2013142875A1 (en) 2013-09-26
IL269205B (en) 2020-06-30
HUE053156T2 (hu) 2021-06-28
CA2867723C (en) 2022-11-08
EP4252855A3 (en) 2023-11-15
KR20140139009A (ko) 2014-12-04
EP2827900A1 (en) 2015-01-28
JP2015514075A (ja) 2015-05-18
JP2024019526A (ja) 2024-02-09
IL234627B (en) 2018-10-31
TR201808450T4 (tr) 2018-07-23
PT3400943T (pt) 2021-02-02
JP2019081792A (ja) 2019-05-30
PH12014502032A1 (en) 2014-11-24
HUE037966T2 (hu) 2018-09-28
JP2022190126A (ja) 2022-12-22
KR102317166B1 (ko) 2021-10-26
JP2021178820A (ja) 2021-11-18
KR20210131426A (ko) 2021-11-02
RU2014142700A (ru) 2016-05-20
EP4252855A2 (en) 2023-10-04
AU2021261849A1 (en) 2021-12-02
SI3400943T1 (sl) 2021-03-31
JP7404485B2 (ja) 2023-12-25
CY1120204T1 (el) 2018-12-12
RU2018138976A3 (es) 2022-04-08
LT2827900T (lt) 2018-05-10
PL3400943T3 (pl) 2021-06-14
CA2867723A1 (en) 2013-09-26
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
CN104203279A (zh) 2014-12-10
MX354024B (es) 2018-02-08
CN109223791A (zh) 2019-01-18
CL2014002497A1 (es) 2014-11-14
AU2017272232A1 (en) 2018-01-04
US20230190749A1 (en) 2023-06-22
KR20200115656A (ko) 2020-10-07
KR102160462B1 (ko) 2020-09-28
UA122044C2 (uk) 2020-09-10
NZ741615A (en) 2019-10-25
US20150110780A1 (en) 2015-04-23
CY1123837T1 (el) 2022-05-27
MY202114A (en) 2024-04-04
AU2013234921A1 (en) 2014-10-02
RU2018138976A (ru) 2018-12-06
ES2855142T3 (es) 2021-09-23
AU2017272232C1 (en) 2019-08-15
EP3842044A1 (en) 2021-06-30
US20190255051A1 (en) 2019-08-22
HRP20180659T1 (hr) 2018-06-01
AU2017272232B2 (en) 2019-02-28
US11504370B2 (en) 2022-11-22
EP3400943B1 (en) 2020-12-02
AU2019203618B2 (en) 2021-08-05
RS57140B1 (sr) 2018-07-31
MX2014011437A (es) 2014-11-10
NZ724544A (en) 2018-05-25
AU2019203618A1 (en) 2019-06-13
EP2827900B1 (en) 2018-03-21
JP6898960B2 (ja) 2021-07-07
CN104203279B (zh) 2018-10-30
IL269205A (en) 2019-11-28
RU2672575C2 (ru) 2018-11-16
SI2827900T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
CO7071139A2 (es) Tratamiento contra el cáncer cerebral
CR20150316A (es) Compuestos y sus métodos de empleo
AR091837A1 (es) Compuestos para inmunoterapia dirigida
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
GB201209613D0 (en) New compounds
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY36075A (es) Derivados de tubulisina
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
EA201400178A1 (ru) Лечение рака молочной железы
NI201500140A (es) Compuestos y composiciones terapéuticos
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
CR20120202A (es) Métodos y composiciones para tratar cáncer
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo